What Happened?
Shares of telehealth company Hims & Hers Health (NYSE: HIMS) jumped 4.1% in the morning session after the company announced plans to expand into Canada with a weight-loss solution centered on generic semaglutide. The telehealth company intends to launch its weight loss program in Canada in 2026, a move timed to coincide with the expected global debut of a generic version of semaglutide. Semaglutide is the active ingredient in popular and effective, but costly, branded weight-loss drugs like Ozempic and Wegovy. Hims & Hers aims to capture a significant portion of the Canadian market, where the company notes that about two-thirds of adults are overweight or obese.
By offering a more affordable generic alternative through its digital health platform, which includes access to licensed medical providers and personalized care, the company is positioning itself for significant growth. This strategic international expansion follows the company's recent acquisition of European telehealth company ZAVA and signals a clear strategy to become a key player in the global weight management market.
After the initial pop the shares cooled down to $48.95, down 0.1% from previous close.
Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Hims & Hers Health’s shares are extremely volatile and have had 94 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
Hims & Hers Health is up 94.2% since the beginning of the year, but at $48.95 per share, it is still trading 28.8% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $4,759.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
